Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
25
DRUG Quote, Financials, Valuation and Earnings
Last price:
$37.60
Seasonality move
:
-40.69%
Day range:
$37.74 - $39.54
52-week range:
$0.93 - $79.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
60.60x
Volume:
40.1K
Avg. volume:
163.3K
1-year change:
2481.23%
Market cap:
$269.8M
Revenue:
--
EPS (TTM):
-$0.68
Analysts' Opinion
-
Consensus RatingBright Minds Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Bright Minds Biosciences has an estimated downside of -- from its current price of $38.69.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $38.69.
Fair Value
-
According to the consensus of 0 analysts, Bright Minds Biosciences has -- downside to fair value with a price target of -- per share.
DRUG vs. S&P 500
-
Over the past 5 trading days, Bright Minds Biosciences has underperformed the S&P 500 by -2.04% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bright Minds Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bright Minds Biosciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bright Minds Biosciences reported revenues of --.
Earnings Growth
-
Bright Minds Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bright Minds Biosciences reported earnings per share of $0.04.
Enterprise value:
265.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-140.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$11.8M | -$6.6M | -$2.7M | -$1.1M | $171.5K | |
| EBITDA | -$11.8M | -$6.5M | -$2.6M | -$1.1M | $184.8K | |
| Diluted EPS | -$4.97 | -$1.94 | -$0.68 | -$0.29 | $0.04 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $17.9M | $6.8M | $6.3M | $4.6M | |
| Total Assets | -- | $17.9M | $6.8M | $6.4M | $4.6M | |
| Current Liabilities | -- | $260.4K | $299K | $543.9K | $130.4K | |
| Total Liabilities | -- | $260.4K | $299K | $554.5K | $130.4K | |
| Total Equity | -- | $17.7M | $6.5M | $5.8M | $4.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.7M | -$6M | -$1.9M | -$1.2M | $193K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -$512K | $5.6M | $588K | -$6.4K | -$25.3K | |
| Free Cash Flow | -$10.7M | -$6M | -$1.9M | -$1.2M | $193K | |
DRUG
Sector
Market Cap
$269.8M
$45.6M
Price % of 52-Week High
48.96%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
2481.23%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$39.17
200-day SMA
Buy
Level
$11.11
Bollinger Bands (100)
Buy
Level
0.28 - 41.88
Chaikin Money Flow
Sell
Level
-139.1M
20-day SMA
Sell
Level
$39.97
Relative Strength Index (RSI14)
Sell
Level
49.39
ADX Line
Sell
Level
15.71
Williams %R
Neutral
Level
-79.3732
50-day SMA
Sell
Level
$41.03
MACD (12, 26)
Buy
Level
0.11
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
664M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Stock Forecast FAQ
In the current month, DRUG has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DRUG average analyst price target in the past 3 months is --.
-
Where Will Bright Minds Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bright Minds Biosciences share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Bright Minds Biosciences?
Analysts are divided on their view about Bright Minds Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bright Minds Biosciences is a Sell and believe this share price will rise from its current level to --.
-
What Is Bright Minds Biosciences's Price Target?
The price target for Bright Minds Biosciences over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DRUG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bright Minds Biosciences is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DRUG?
You can purchase shares of Bright Minds Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bright Minds Biosciences shares.
-
What Is The Bright Minds Biosciences Share Price Today?
Bright Minds Biosciences was last trading at $37.60 per share. This represents the most recent stock quote for Bright Minds Biosciences. Yesterday, Bright Minds Biosciences closed at $38.69 per share.
-
How To Buy Bright Minds Biosciences Stock Online?
In order to purchase Bright Minds Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.05% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.62% over the past day.
